Investigates miR-155-5p's role in osteosarcoma progression and resistance to cisplatin, suggesting new treatment strategies.
Osteosarcoma remains challenging to treat due to metastasis and chemoresistance. This study investigated the role and mechanisms of miR-155-5p in osteosarcoma progression and chemoresistance. We analyzed miR-155-5p expression in clinical datasets and evaluated its biological functions in osteosarcoma cell lines through proliferation, migration, and apoptosis assays. Target identification and validation were performed using bioinformatics analysis, dual-luciferase reporter assays, and molecular studies. Cisplatin-resistant cells were used to examine chemoresistance mechanisms. Elevated miR-155-5p expression correlated with poor survival in patients and was significantly upregulated in osteosarcoma. miR-155-5p promoted proliferation and migration while inhibiting apoptosis across multiple cell lines. Mechanistically, miR-155-5p directly targeted SOCS1, leading to decreased STAT1 and increased c-Fos expression. This axis modulated downstream effectors including P-glycoprotein, Bcl-2, and Bax. In cisplatin-resistant cells, dysregulation of the miR-155-5p/SOCS1 axis contributed to drug resistance. miR-155-5p functions as an oncogenic microRNA by targeting the SOCS1/STAT1/c-Fos axis, promoting malignant behaviors and chemoresistance in osteosarcoma. This pathway represents a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: